personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Anti-VEGF treatment of women with childbearing potential

Session Details

Session Title: Vascular Diseases III

Session Date/Time: Sunday 29/09/2013 | 08:00-10:00

Paper Time: 08:24

Venue: Hall 3 (Level 0)

First Author: M.Gajdosova SLOVAKIA

Co Author(s):    M. Ondrejkova              

Abstract Details

Purpose:

To report the clinical course of the pregnancy after intravitreal treatment with bevacizumab

Setting:

OFTAL s.r.o, Specialized Ophtalmology Hospital, Zvolen, Slovakia

Methods:

- Case report: 27 years old woman with active choroidal neovascularisation (CNV) of inflammatory origin (HSV positivity) above the fovea in her right eye was administered intravitreal (ivt) injections of bevacizumab, after discussing the treatment-related risks and benefits.

Results:

In the beginning her BCVA was 30 ETDRS letter score and CRT 793 um. After 3 ivt injections of bevacizumab (1,25mg in 0,05 ml) BCVA substantionaly improved to 59 ETDRS letters score (+29 letters gain) and CRT decreased to 223 um (-570 um reduction). After 3rd injection, 8 week of pregnancy was confirmed. During pregnancy, fetal ultrasound and ophthalmic examination were performed monthly. BCVA and OCT stayed stable and did not required any further ivt treatment. She had an uneventful prenatal course and delivered a healthy full-term infant.

Conclusions:

In this case ivt anti-VEGF therapy lead to significant BCVA improvement and stabilisation of CNV. Despite of ivt administration of the last dose of bevacizumab in the beginning of the pregnancy, this was not accompanied by any negative systemic side effects in both mother and the fetus. Further studies are warranted to provide more detailed information about this treatment and the related risks in pregnant women.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy